GSK (LON:GSK) Given “Hold” Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of GSK (LON:GSK) in a research note published on Monday morning, MarketBeat Ratings reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,950 target price on the stock.

Several other research analysts have also recently weighed in on GSK. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research report on Thursday, May 28th. Citigroup reduced their target price on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of GBX 2,041.43.

GSK Price Performance

GSK stock opened at GBX 1,961 on Monday. GSK has a 12 month low of GBX 1,288.61 and a 12 month high of GBX 2,282. The stock’s 50 day moving average is GBX 1,933.21 and its 200-day moving average is GBX 1,989.71. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. The company has a market capitalization of £78.55 billion, a price-to-earnings ratio of 13.80, a PEG ratio of 1.24 and a beta of 0.30.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The company had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. Equities research analysts expect that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In related news, insider Vishal Sikka acquired 1,266 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average price of GBX 5,069 per share, for a total transaction of £64,173.54. Also, insider Jeannie Lee acquired 802 shares of the stock in a transaction on Monday, June 22nd. The shares were bought at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Insiders have purchased a total of 7,625 shares of company stock valued at $21,347,004 in the last three months. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.